Hybrid Nanoparticles of Extracellular Vesicles and Gemcitabine Prodrug-Loaded Liposomes with Enhanced Targeting Ability for Effective PDAC Treatment

Bora Kim, Heewon Park, H.‐j. Liu, Sejin Kim, Yong-Kyu Lee, Yeu‐Chun KimACS 2024 · DOI

Abstract

Liposomes are applied to various anticancer treatments as representative drug delivery carriers. However, liposomes do not have their own targeting properties; therefore, there are limitations in drug delivery to specific tissues or cells. High targetability in drug delivery is an important factor in improving bioavailability and drug efficacy and reducing side effects; recent research has been actively investigated to modify the surface of liposomes to give them specific functions. In this study, we studied a drug delivery system for anticancer treatment that enhances targeting ability through fusion with exosomes on the surface of liposomes. We designed exosome-liposome hybrid nanoparticles loaded with a gemcitabine prodrug as a treatment for pancreatic ductal adenocarcinoma (PDAC). Membrane fusion with exosomes shows excellent targeting ability to pancreatic cancer cells due to intrinsic targeting ability and expansion of the macropinocytosis pathway.
BibTeX
@inproceedings{kim2024hybrid,
  author = {Bora Kim and Heewon Park and H.‐J. LIU and Sejin Kim and Yong-Kyu Lee and Yeu‐Chun Kim},
  title = {{Hybrid Nanoparticles of Extracellular Vesicles and Gemcitabine Prodrug-Loaded Liposomes with Enhanced Targeting Ability for Effective PDAC Treatment}},
  booktitle = {ACS},
  year = {2024},
  doi = {10.1021/acsabm.4c00658},
}

Loading related content...

Figure